Monte Rosa reports Q4 2021 net loss $23.4M; cash $351.4M; on track for MRT-2359 IND mid-2022

Monte Rosa Therapeutics, Inc.

Net loss Q4 2021 $23.4M vs $19.7M in Q4 2020; FY 2021 loss $74.0M vs $35.9M in 2020.
Cash, cash equivalents and restricted cash $351.4M as of Dec 31, 2021, expected runway into late 2024.
R&D expenses Q4 2021 $18.1M, up from $9.9M in Q4 2020; G&A expenses $5.3M vs $2.1M.
IND filing for MRT-2359 (GSPT1 degrader) targeted mid-2022; CDK2 and NEK7 programs in lead optimization.
Promoted Jullian Jones to CBO and Phil Nickson to General Counsel; partnered with Weizmann Institute on covalent chemistry.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.